기사

 Prodizen, a company specializing in regenerative medicine, will participate in the Spring Academic Conference of the hereinafter referred to as DPMO, which will be held on May 3 at COEX in Seoul.

The DPMO conference is one of the largest aesthetic medicine academic events in Korea, where the latest research findings and clinical knowledge in healthcare and anti-aging fields—such as dermatologic lasers, botulinum toxin, fillers, thread lifting, obesity, and hair loss treatments—are shared. Held annually at COEX, the event has established itself as a major gathering for both domestic and international medical professionals and industry stakeholders.

At this year’s conference, Prodizen will present the latest clinical strategies in blood-based regenerative medicine in collaboration with its partner clinic, O& Clinic. Dr. Myeongjun Oh of O& Clinic will deliver a lecture titled “Clinical Evolution of Blood-Based Regenerative Platforms: Personalized Signal Therapies for Skin Restoration” in Room C at 3:50 PM.

The presentation will focus on clinical applications of PRP (Platelet-Rich Plasma) and GFC-based regenerative therapies, highlighting practical treatment strategies applicable to skin regeneration and anti-aging. In particular, it will cover growth factor-based signaling mechanisms and personalized therapeutic approaches for enhancing skin recovery.

O& Clinic, a long-term partner of Prodizen, has collaboratively developed regenerative medicine-based treatment protocols and accumulated clinical experience in skin and anti-aging procedures. This experience, supported by real-world clinical data, will be shared during the presentation. Prodizen continues to expand its business beyond product supply by working closely with partner clinics to develop clinically grounded regenerative medicine solutions.

Since its establishment in 1998, Prodizen has built strong technological expertise in regenerative medicine and was the first in Korea to localize PRP kits. Its GFC (Growth Factor Concentrate), developed based on PRP technology, is designed to selectively isolate and concentrate growth factors—beyond platelets—through a precise separation process, resulting in higher growth factor concentrations compared to conventional PRP. The company manages the entire production process through its own GMP-certified manufacturing facility and supplies its products to global markets, including the United States, Europe, and the Middle East.

A representative from Prodizen stated, “Through this conference, we are able to share more concrete insights into regenerative medicine treatment strategies currently being evaluated in real clinical settings. Moving forward, we will continue to expand the clinical applications of blood-based regenerative therapies and further advance treatment protocols based on our collaboration with partner medical institutions.”

Participation in the DPMO conference is available through pre-registration. When registering, entering the referral code “Prodizen0503” allows for a more convenient application process.

Source: Medisobiza News